Search

Search Constraints

You searched for: Author/Creator Grande, C.

Search Results

2. AUTOLOGOUS STEM CELL TRANSPLANTATION MAY POTENTIALLY ABROGATE THE NEGATIVE PROGNOSTIC EFFECT OF EARLY RELAPSE AFTER CHEMO OR INMUNOCHEMOTHERAPY IN FOLLICULAR LYMPHOMA. (June 2017)

3. EVALUATION OF BONE MARROW INFILTRATION BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: SUB‐STUDY OF A PHASE 2 GELTAMO CLINICAL TRIAL. (12th June 2019)

4. Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from the Spanish group GELTAMO. (June 2017)

5. LONG‐TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT‐2008‐01). (June 2017)

6. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL. (23rd June 2022)

7. P1132: PET INTERIM RESULTS PREDICT PROGRESSION-FREE-SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS WITH ADVANCED STAGE. (23rd June 2022)

8. P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS. (23rd June 2022)

9. P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. (23rd June 2022)

10. PHASE 2 RANDOMIZED TRIAL COMPARING STANDARD RCHOP VERSUS BRCAP AS FIRST LINE TREATMENT IN YOUNG PATIENTS WITH HIGH‐RISK DLBCL. A STUDY FROM SPANISH GROUP GELTAMO. (June 2017)